[
  {
    "ts": null,
    "headline": "Incyte Announces Phase 3 Data for it's Retifanlimab (Zynyz®?) in Patients with Squamous Cell Carcinoma of the Anal Canal Published in The Lancet",
    "summary": "Incyte announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab , a humanized monoclonal antibody targeting programmed death receptor-1 , in combination with...",
    "url": "https://finnhub.io/api/news?id=93115462ee319cbf6ae096702012e618b8c90e6ecc285f0dcbb0bf8226ce739f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749765935,
      "headline": "Incyte Announces Phase 3 Data for it's Retifanlimab (Zynyz®?) in Patients with Squamous Cell Carcinoma of the Anal Canal Published in The Lancet",
      "id": 135225065,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "Incyte announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab , a humanized monoclonal antibody targeting programmed death receptor-1 , in combination with...",
      "url": "https://finnhub.io/api/news?id=93115462ee319cbf6ae096702012e618b8c90e6ecc285f0dcbb0bf8226ce739f"
    }
  },
  {
    "ts": null,
    "headline": "Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet",
    "summary": "POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously...",
    "url": "https://finnhub.io/api/news?id=afd3481e4638f0bd78f15d048b5faf02364d9bcb2d720580ef873da4cf48341d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749753964,
      "headline": "Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet",
      "id": 135224241,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously...",
      "url": "https://finnhub.io/api/news?id=afd3481e4638f0bd78f15d048b5faf02364d9bcb2d720580ef873da4cf48341d"
    }
  },
  {
    "ts": null,
    "headline": "Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-To-Treat Conditions",
    "summary": "Specialised Therapeutics announced the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte , to launch and...",
    "url": "https://finnhub.io/api/news?id=8fcade516feabe2bd41e897b59c72e064e67ce720468c5ce927b47f35b930786",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749738042,
      "headline": "Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-To-Treat Conditions",
      "id": 135221624,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "Specialised Therapeutics announced the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte , to launch and...",
      "url": "https://finnhub.io/api/news?id=8fcade516feabe2bd41e897b59c72e064e67ce720468c5ce927b47f35b930786"
    }
  },
  {
    "ts": null,
    "headline": "Specialised Therapeutics Expands Partnership With Incyte",
    "summary": "Specialised Therapeutics: * SPECIALISED THERAPEUTICS: EXPANDS PARTNERSHIP WITH INCYTETOINCLUDE TWO ADDITIONAL THERAPIES FOR HARD-TO-TREAT CONDITIONS * SPECIALISED...",
    "url": "https://finnhub.io/api/news?id=fec3727c83db7eb3e0bcd3f1803cdc5d1caeb6586cc04ef62cdd9f128978f57e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749732610,
      "headline": "Specialised Therapeutics Expands Partnership With Incyte",
      "id": 135217058,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "Specialised Therapeutics: * SPECIALISED THERAPEUTICS: EXPANDS PARTNERSHIP WITH INCYTETOINCLUDE TWO ADDITIONAL THERAPIES FOR HARD-TO-TREAT CONDITIONS * SPECIALISED...",
      "url": "https://finnhub.io/api/news?id=fec3727c83db7eb3e0bcd3f1803cdc5d1caeb6586cc04ef62cdd9f128978f57e"
    }
  }
]